SCHEMBL2748836

SCHEMBL2748836

CC1CN(C(=O)c2cccc(-c3cnc(N)c(-c4nc5ccccc5s4)c3)c2)CC(C)O1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.47
LRRK2 Q5S007 1/20 0.45
FYN P06241 1/20 0.45
HPGD P15428 3/20 0.42
ALDH1A1 P00352 3/20 0.42
ATR Q13535 3/20 0.42
LMNA P02545 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CDK1 P06493 1/20 0.42
CDK2 P24941 1/20 0.42
MKNK1 Q9BUB5 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
UBE2M P61081 2/20 0.40
DCUN1D1 Q96GG9 2/20 0.40
MAP4K4 O95819 1/20 0.40
GAA P10253 1/20 0.40
GFER P55789 1/20 0.40
ALOX5AP P20292 1/20 0.40
FEN1 P39748 1/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2748832 1.00 HSD17B10 (0.47) HSD17B10LRRK2FYNHPGDALDH1A1
SCHEMBL2749334 0.90 FYN (0.47) LRRK2FYNALDH1A1ATRLMNA
SCHEMBL2749333 0.90 FYN (0.47) LRRK2FYNALDH1A1ATRLMNA
SCHEMBL2749692 0.90 FYN (0.45) LRRK2FYNALDH1A1ATRLMNA
SCHEMBL2749695 0.90 FYN (0.45) LRRK2FYNALDH1A1ATRLMNA
SCHEMBL2749700 0.86 ATR (0.52) LRRK2FYNHPGDALDH1A1ATR
SCHEMBL2749343 0.85 FYN (0.62) HSD17B10LRRK2FYNHPGDALDH1A1
SCHEMBL2750485 0.85 FYN (0.53) LRRK2FYNALDH1A1ATRLMNA
SCHEMBL2750571 0.85 ATR (0.51) LRRK2FYNHPGDALDH1A1ATR
SCHEMBL2747927 0.85 ATR (0.55) LRRK2FYNALDH1A1ATRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178668-B2 2-aminopyridine kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-05-15 US disclosed
EP-2265270-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2010-12-29 EP disclosed
WO-2009099982-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2009-08-13 WO disclosed
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS ERBB2, ABL2, TIE1 HSD17B10 4249/4885LRRK2 175/4885FYN 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.